The Valley Desk

NCT05028634 · Interventional trial

Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy

Overall registry status Completed

Phase 3

Conditions Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov